This ACTION registry analysis of 94 children with heart failure found no difference in 30-day readmission or mortality whether beta-blockers were started during an inpatient admission or in the outpatient setting. The findings suggest both approaches are safe, though larger datasets are needed to confirm them.
Safety of Inpatient and Outpatient Beta Blocker Initiation in Pediatric Heart Failure Read More »
A new multi-center study explores the off-label use of SGLT2 inhibitors in children and adolescents with heart failure, highlighting real-world safety data and underscoring the need for prospective trials.
Use of SGLT2 inhibitors in pediatric heart failure: a multi-center study Read More »
See Victor Benvenuto, MD’s Poster Presentation.
ACTION @ ISHLT ’25: Beta-Blocker Initiation in Pediatric Heart Failure Read More »
Patients with congenital heart disease (CHD) frequently have had valve interventions, including replacement with a mechanical valve. The impact of a mechanical valve on clinical outcomes in patients undergoing ventricular assist device (VAD) implantation is not well characterized.
